Literature DB >> 30688695

Risk Assessment in Patients with a Left Ventricular Assist Device Across INTERMACS Profiles Using Bayesian Analysis.

Manreet K Kanwar1, Lisa C Lohmueller2, Jeffrey Teuteberg3, Robert L Kormos4, Joseph G Rogers5, Raymond L Benza1, Joann Lindenfeld6, Colleen McIlvennan7, Stephen H Bailey1, Srinivas Murali1, James F Antaki8.   

Abstract

Current risk stratification models to predict outcomes after a left ventricular assist device (LVAD) are limited in scope. We assessed the performance of Bayesian models to stratify post-LVAD mortality across various International Registry for Mechanically Assisted Circulatory Support (INTERMACS or IM) Profiles, device types, and implant strategies. We performed a retrospective analysis of 10,206 LVAD patients recorded in the IM registry from 2012 to 2016. Using derived Bayesian algorithms from 8,222 patients (derivation cohort), we applied the risk-prediction algorithms to the remaining 2,055 patients (validation cohort). Risk of mortality was assessed at 1, 3, and 12 months post implant according to disease severity (IM profiles), device type (axial versus centrifugal) and strategy (bridge to transplantation or destination therapy). Fifteen percentage (n = 308) were categorized as IM profile 1, 36% (n = 752) as profile 2, 33% (n = 672) as profile 3, and 15% (n = 311) as profile 4-7 in the validation cohort. The Bayesian algorithms showed good discrimination for both short-term (1 and 3 months) and long-term (1 year) mortality for patients with severe HF (Profiles 1-3), with the receiver operating characteristic area under the curve (AUC) between 0.63 and 0.74. The algorithms performed reasonably well in both axial and centrifugal devices (AUC, 0.68-0.74), as well as bridge to transplantation or destination therapy indication (AUC, 0.66-0.73). The performance of the Bayesian models at 1 year was superior to the existing risk models. Bayesian algorithms allow for risk stratification after LVAD implantation across different IM profiles, device types, and implant strategies.

Entities:  

Mesh:

Year:  2019        PMID: 30688695      PMCID: PMC6610699          DOI: 10.1097/MAT.0000000000000910

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  13 in total

1.  INTERMACS profiles and modifiers: Heterogeneity of patient classification and the impact of modifiers on predicting patient outcome.

Authors:  Jennifer Cowger; Palak Shah; John Stulak; Simon Maltais; Keith D Aaronson; James K Kirklin; Francis D Pagani; Christopher Salerno
Journal:  J Heart Lung Transplant       Date:  2015-11-06       Impact factor: 10.247

Review 2.  Artificial Intelligence in Cardiology.

Authors:  Kipp W Johnson; Jessica Torres Soto; Benjamin S Glicksberg; Khader Shameer; Riccardo Miotto; Mohsin Ali; Euan Ashley; Joel T Dudley
Journal:  J Am Coll Cardiol       Date:  2018-06-12       Impact factor: 24.094

3.  Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation.

Authors:  K D Aaronson; J S Schwartz; T M Chen; K L Wong; J E Goin; D M Mancini
Journal:  Circulation       Date:  1997-06-17       Impact factor: 29.690

4.  Low Accuracy of the HeartMate Risk Score for Predicting Mortality Using the INTERMACS Registry Data.

Authors:  Manreet K Kanwar; Lisa C Lohmueller; Robert L Kormos; Natasha A Loghmanpour; Raymond L Benza; Robert J Mentz; Stephen H Bailey; Srinivas Murali; James F Antaki
Journal:  ASAIO J       Date:  2017 May/Jun       Impact factor: 2.872

Review 5.  Eighth annual INTERMACS report: Special focus on framing the impact of adverse events.

Authors:  James K Kirklin; Francis D Pagani; Robert L Kormos; Lynne W Stevenson; Elizabeth D Blume; Susan L Myers; Marissa A Miller; J Timothy Baldwin; James B Young; David C Naftel
Journal:  J Heart Lung Transplant       Date:  2017-07-15       Impact factor: 10.247

6.  Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification.

Authors:  Andrew J Boyle; Deborah D Ascheim; Mark J Russo; Robert L Kormos; Ranjit John; Yoshifumi Naka; Annetine C Gelijns; Kimberly N Hong; Jeffrey J Teuteberg
Journal:  J Heart Lung Transplant       Date:  2010-12-18       Impact factor: 10.247

7.  A new Bayesian network-based risk stratification model for prediction of short-term and long-term LVAD mortality.

Authors:  Natasha A Loghmanpour; Manreet K Kanwar; Marek J Druzdzel; Raymond L Benza; Srinivas Murali; James F Antaki
Journal:  ASAIO J       Date:  2015 May-Jun       Impact factor: 2.872

8.  The Heartmate Risk Score predicts morbidity and mortality in unselected left ventricular assist device recipients and risk stratifies INTERMACS class 1 patients.

Authors:  Luigi Adamo; Michael Nassif; Anjan Tibrewala; Eric Novak; Justin Vader; Scott C Silvestry; Akinobu Itoh; Gregory A Ewald; Douglas L Mann; Shane J LaRue
Journal:  JACC Heart Fail       Date:  2015-03-11       Impact factor: 12.035

9.  INTERMACS profiles of advanced heart failure: the current picture.

Authors:  Lynne Warner Stevenson; Francis D Pagani; James B Young; Mariell Jessup; Leslie Miller; Robert L Kormos; David C Naftel; Karen Ulisney; Patrice Desvigne-Nickens; James K Kirklin
Journal:  J Heart Lung Transplant       Date:  2009-06       Impact factor: 10.247

10.  A Bayesian Model to Predict Right Ventricular Failure Following Left Ventricular Assist Device Therapy.

Authors:  Natasha A Loghmanpour; Robert L Kormos; Manreet K Kanwar; Jeffrey J Teuteberg; Srinivas Murali; James F Antaki
Journal:  JACC Heart Fail       Date:  2016-06-08       Impact factor: 12.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.